Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 13

1.

Mortality after traumatic brain injury and the effect of posttraumatic epilepsy.

Uski J, Lamusuo S, Teperi S, Löyttyniemi E, Tenovuo O.

Neurology. 2018 Aug 28;91(9):e878-e883. doi: 10.1212/WNL.0000000000006077. Epub 2018 Aug 1.

PMID:
30068629
2.

Neurotransmitters behind pain relief with transcranial magnetic stimulation - positron emission tomography evidence for release of endogenous opioids.

Lamusuo S, Hirvonen J, Lindholm P, Martikainen IK, Hagelberg N, Parkkola R, Taiminen T, Hietala J, Helin S, Virtanen A, Pertovaara A, Jääskeläinen SK.

Eur J Pain. 2017 Oct;21(9):1505-1515. doi: 10.1002/ejp.1052. Epub 2017 May 11.

PMID:
28493519
3.

The analgesic effect of therapeutic rTMS is not mediated or predicted by comorbid psychiatric or sleep disorders.

Lindholm P, Lamusuo S, Taiminen T, Virtanen A, Pertovaara A, Forssell H, Hagelberg N, Jääskeläinen S.

Medicine (Baltimore). 2016 Nov;95(44):e5231.

4.

Right secondary somatosensory cortex-a promising novel target for the treatment of drug-resistant neuropathic orofacial pain with repetitive transcranial magnetic stimulation.

Lindholm P, Lamusuo S, Taiminen T, Pesonen U, Lahti A, Virtanen A, Forssell H, Hietala J, Hagelberg N, Pertovaara A, Parkkola R, Jääskeläinen S.

Pain. 2015 Jul;156(7):1276-83. doi: 10.1097/j.pain.0000000000000175.

PMID:
25830924
5.

Variation in the dopamine D2 receptor gene plays a key role in human pain and its modulation by transcranial magnetic stimulation.

Jääskeläinen SK, Lindholm P, Valmunen T, Pesonen U, Taiminen T, Virtanen A, Lamusuo S, Forssell H, Hagelberg N, Hietala J, Pertovaara A.

Pain. 2014 Oct;155(10):2180-7. doi: 10.1016/j.pain.2014.08.029. Epub 2014 Aug 29.

PMID:
25180011
6.

Long-term epilepsy surgery outcomes in patients with MRI-negative temporal lobe epilepsy.

Immonen A, Jutila L, Muraja-Murro A, Mervaala E, Äikiä M, Lamusuo S, Kuikka J, Vanninen E, Alafuzoff I, Ikonen A, Vanninen R, Vapalahti M, Kälviäinen R.

Epilepsia. 2010 Nov;51(11):2260-9. doi: 10.1111/j.1528-1167.2010.02720.x. Epub 2010 Sep 24.

7.

Substantial thalamostriatal dopaminergic defect in Unverricht-Lundborg disease.

Korja M, Kaasinen V, Lamusuo S, Parkkola R, Någren K, Marttila RJ.

Epilepsia. 2007 Sep;48(9):1768-1773. doi: 10.1111/j.1528-1167.2007.01118.x. Epub 2007 May 1.

8.

Hyperostosis frontalis interna as a novel finding in Unverricht-Lundborg disease.

Korja M, Kaasinen V, Lamusuo S, Marttila RJ, Parkkola R.

Neurology. 2007 Mar 27;68(13):1077-8. No abstract available.

PMID:
17389316
9.

[18F]FDG-PET reveals temporal hypometabolism in patients with temporal lobe epilepsy even when quantitative MRI and histopathological analysis show only mild hippocampal damage.

Lamusuo S, Jutila L, Ylinen A, Kälviäinen R, Mervaala E, Haaparanta M, Jääskeläinen S, Partanen K, Vapalahti M, Rinne J.

Arch Neurol. 2001 Jun;58(6):933-9.

PMID:
11405808
10.

[11 C]Flumazenil binding in the medial temporal lobe in patients with temporal lobe epilepsy: correlation with hippocampal MR volumetry, T2 relaxometry, and neuropathology.

Lamusuo S, Pitkänen A, Jutila L, Ylinen A, Partanen K, Kälviäinen R, Ruottinen HM, Oikonen V, Någren K, Lehikoinen P, Vapalahti M, Vainio P, Rinne JO.

Neurology. 2000 Jun 27;54(12):2252-60.

PMID:
10881249
11.

[18F]FDG-PET and whole-scalp MEG localization of epileptogenic cortex.

Lamusuo S, Forss N, Ruottinen HM, Bergman J, Mäkelä JP, Mervaala E, Solin O, Rinne JK, Ruotsalainen U, Ylinen A, Vapalahti M, Hari R, Rinne JO.

Epilepsia. 1999 Jul;40(7):921-30.

13.

Comparison of [18F]FDG-PET, [99mTc]-HMPAO-SPECT, and [123I]-iomazenil-SPECT in localising the epileptogenic cortex.

Lamusuo S, Ruottinen HM, Knuuti J, Härkönen R, Ruotsalainen U, Bergman J, Haaparanta M, Solin O, Mervaala E, Nousiainen U, Jääskeläinen S, Ylinen A, Kälviäinen R, Rinne JK, Vapalahti M, Rinne JO.

J Neurol Neurosurg Psychiatry. 1997 Dec;63(6):743-8.

Supplemental Content

Loading ...
Support Center